Cargando…
Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
OBJECTIVE: Myasthenia gravis (MG) is an autoimmune condition in which neurotransmission is impaired by binding of autoantibodies to acetylcholine receptors (AChR) or, in a minority of patients, to muscle specific kinase (MuSK). There are differences in the dominant IgG subclass, pathogenic mechanism...
Autores principales: | Lee, Jae‐Yun, Stathopoulos, Panos, Gupta, Sasha, Bannock, Jason M., Barohn, Richard J., Cotzomi, Elizabeth, Dimachkie, Mazen M., Jacobson, Leslie, Lee, Casey S., Morbach, Henner, Querol, Luis, Shan, Jing‐Li, Vander Heiden, Jason A., Waters, Patrick, Vincent, Angela, Nowak, Richard J., O'Connor, Kevin C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891998/ https://www.ncbi.nlm.nih.gov/pubmed/27547772 http://dx.doi.org/10.1002/acn3.311 |
Ejemplares similares
-
Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015) -
Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023) -
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019) -
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022) -
Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)